Public Release: 

Hispanics largely undertreated for high cholesterol

Abstract 13457 (Hall A2, Poster M 2146)

American Heart Association

Only one-third to one-half of Hispanics eligible to be treated with cholesterol-lowering statins are taking them, according to a study presented at the American Heart Association's Scientific Sessions 2015.

Researchers evaluated the need for high cholesterol treatment among 16,415 U.S. Hispanic/Latino adults. They found:

  • 10.4 percent were being treated with statins.
  • 20.5 percent were eligible for treatment based on recommendations for statin therapy eligibility under the 3rd National Cholesterol Education Program Adult Treatment Panel.
  • 32.1 percent were eligible for the therapy under the 2013 American College of Cardiology/American Heart Association (ACC/AHA) treatment guidelines.

The proportion of statin-eligible adults grew among older adults according to both recommendations and among males in the ACC/AHA guidelines. There was also an increase in eligibility for statin therapy in middle-aged adults.

Researchers said regardless of the definition for statin eligibility, Hispanics are largely undertreated.


Note: Actual presentation is 2 p.m. ET, Monday, Nov. 9, 2015.

Additional Resources:

  • Hispanics and Heart Disease, Stroke
  • For more news from the AHA's Scientific Sessions 2015 follow us on Twitter @HeartNews # AHA15.

Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at

For Media Inquiries and AHA Spokesperson Perspective:

AHA News Media in Dallas: (214) 706-1173
AHA News Media Office, Nov. 7-11, 2015
at the Orange County Convention Center: (407) 685-5401
For Public Inquiries: (800) AHA-USA1 (242-8721) and
Life is why, science is how . . . we help people live longer, healthier lives.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.